Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Halaven is indicated for:
Pharmacology
Eribulin stops microtubules from growing, but it doesn't affect their shortening phase. It also gathers tubulin into clumps that can't do any useful work. Its action is antimitotic and based on tubulin. This blocks the cell cycle at the G2/M stage and breaks up the mitotic spindles, and after the cells stay blocked in mitosis for a long time, they die by apoptosis.
Eribulin also acted on human breast cancer cells in other ways. In laboratory (in vitro) studies, treated cells changed in shape and in gene expression, and they migrated and invaded less.
In mouse xenograft models of human breast cancer, eribulin treatment was linked with more blood flow (vascular perfusion) and more permeability in the core of the tumour. This reduced hypoxia in the tumour. The genes expressed in tumour samples also changed, in a way associated with a change in phenotype.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
The usual dose of Eribulin is 1.4 mg/m2, given intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.
If a patient has mild hepatic impairment (Child-Pugh A), the dose of Eribulin is 1.1 mg/m2, given intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.
For moderate hepatic impairment (Child-Pugh B), the recommended dose is 0.7 mg/m2, again given intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.
Patients with moderate or severe renal impairment (creatinine clearance (CLcr) 15-49 mL/min) should receive 1.1 mg/m2, given intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.
Pediatric use: the safety and effectiveness of HALAVEN in pediatric patients have not been established.
Side Effects
In metastatic breast cancer, the most common side effects of Eribulin Mesylate (seen in 25% or more of patients) were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea and constipation. In liposarcoma and leiomyosarcoma, the most common side effects (again 25% or more) were fatigue, nausea, alopecia, constipation, peripheral neuropathy, abdominal pain and pyrexia. The most common Grade 3-4 laboratory abnormalities in these two cancers (5% or more) were neutropenia, hypokalemia and hypocalcemia.
Cautions & Contraindications
Warnings & Precautions
Neutropenia: with Eribulin Mesylate, monitor peripheral blood cell counts and adjust the dose as appropriate. Peripheral Neuropathy: watch for signs of neuropathy, and manage it by delaying the dose and adjusting it. Embryo-Fetal Toxicity: the medicine can cause fetal harm, so tell females of reproductive potential about the possible risk to the fetus and advise them to use effective contraception. QT Prolongation: monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. Avoid Eribulin Mesylate in patients with congenital long QT syndrome.
Pregnancy & Breastfeeding
Animal reproduction studies and the way Eribulin works both suggest that it can harm the unborn baby when given to a pregnant woman. There are no data on the use of Eribulin during pregnancy.
Nothing is known about whether eribulin mesylate or its metabolites pass into human milk. The effects on a breastfed infant and on milk production are also not known. No lactation studies were done in animals.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Storage
Keep Eribulin Mesylate at 25°C. Short periods between 15° and 30°C are allowed. Don't freeze it and don't put it in the refrigerator. Leave the vials in their original cartons until they are needed.
Drug Interactions
Common questions about Halaven 0.44 mg/ml
What is Halaven 0.44 mg/ml IV Infusion?
Halaven 0.44 mg/ml IV Infusion is a medicine that contains Eribulin Mesylate. It is made by Radiant Pharmaceuticals Ltd. It belongs to the Cytotoxic Chemotherapy group of medicines.
What is Halaven used for?
Halaven is used for: Cancer.
What are the side effects of Halaven?
In metastatic breast cancer, the most common side effects of Eribulin Mesylate (seen in 25% or more of patients) were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea and constipation. In liposarcoma and leiomyosarcoma, the most common side effects (again 25% or more) were fatigue, nausea, alopecia, constipation, peripheral neuropathy, abdominal pain and pyrexia.
Can I take Halaven during pregnancy or while breastfeeding?
Animal reproduction studies and the way Eribulin works both suggest that it can harm the unborn baby when given to a pregnant woman. There are no data on the use of Eribulin during pregnancy. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
How should I store Halaven?
Keep Eribulin Mesylate at 25°C. Short periods between 15° and 30°C are allowed.
Can I take other medicines with Halaven?
Some medicines can interact with Eribulin Mesylate, for example: Ketoconazole, Rifampicin. Tell your doctor or pharmacist about every medicine you take.
Do I need a prescription for Halaven?
Halaven is a prescription (Rx) medicine. Take it as your doctor advises.